NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$10.73−0.41 (-3.68%)
Close on Nov 18, 2026Market cap $1.25BP/E –Yield –
NovoCure revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
NovoCure's revenue for the twelve months ending Sep 30, 2026 was $725.39M, up 12.9% year over year. For fiscal 2025 it was $655.35M, up 8.3% from the year before. Over ten years it grew 34.8% a year on average. The highest annual figure on record is $655.35M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $655.35M | +8.3% |
| FY2024 | Dec 31, 2024 | $605.22M | +18.8% |
| FY2023 | Dec 31, 2023 | $509.34M | -5.3% |
| FY2022 | Dec 31, 2022 | $537.84M | +0.5% |
| FY2021 | Dec 31, 2021 | $535.03M | +8.2% |
| FY2020 | Dec 31, 2020 | $494.37M | +40.7% |
| FY2019 | Dec 31, 2019 | $351.32M | +41.6% |
| FY2018 | Dec 31, 2018 | $248.07M | +40.1% |
| FY2017 | Dec 31, 2017 | $177.03M | +113.6% |
| FY2016 | Dec 31, 2016 | $82.89M | +150.5% |
| FY2015 | Dec 31, 2015 | $33.09M | +113.6% |
| FY2014 | Dec 31, 2014 | $15.49M | +49.5% |
| FY2013 | Dec 31, 2013 | $10.36M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $193.40M | +15.7% |
| Q2 FY2026 | Jun 30, 2026 | $183.58M | +15.6% |
| Q1 FY2026 | Mar 31, 2026 | $174.06M | +12.3% |
| Q4 FY2025 | Dec 31, 2025 | $174.35M | +8.1% |
| Q3 FY2025 | Sep 30, 2025 | $167.20M | +7.8% |
| Q2 FY2025 | Jun 30, 2025 | $158.81M | +5.6% |
| Q1 FY2025 | Mar 31, 2025 | $154.99M | +11.9% |
| Q4 FY2024 | Dec 31, 2024 | $161.27M | +20.5% |
| Q3 FY2024 | Sep 30, 2024 | $155.10M | +21.8% |
| Q2 FY2024 | Jun 30, 2024 | $150.36M | +19.3% |
| Q1 FY2024 | Mar 31, 2024 | $138.50M | +13.4% |
| Q4 FY2023 | Dec 31, 2023 | $133.78M | +4.2% |
| Q3 FY2023 | Sep 30, 2023 | $127.32M | -2.8% |
| Q2 FY2023 | Jun 30, 2023 | $126.05M | -10.5% |
| Q1 FY2023 | Mar 31, 2023 | $122.18M | -11.2% |
| Q4 FY2022 | Dec 31, 2022 | $128.43M | -3.6% |
| Q3 FY2022 | Sep 30, 2022 | $131.00M | -2.0% |
| Q2 FY2022 | Jun 30, 2022 | $140.87M | +5.5% |
| Q1 FY2022 | Mar 31, 2022 | $137.55M | +2.1% |
| Q4 FY2021 | Dec 31, 2021 | $133.21M | -7.5% |
| Q3 FY2021 | Sep 30, 2021 | $133.61M | +0.7% |
| Q2 FY2021 | Jun 30, 2021 | $133.52M | +15.2% |
| Q1 FY2021 | Mar 31, 2021 | $134.70M | +32.3% |
| Q4 FY2020 | Dec 31, 2020 | $143.95M | +45.1% |
| Q3 FY2020 | Sep 30, 2020 | $132.66M | +44.1% |
| Q2 FY2020 | Jun 30, 2020 | $115.93M | +33.7% |
| Q1 FY2020 | Mar 31, 2020 | $101.83M | +38.9% |
| Q4 FY2019 | Dec 31, 2019 | $99.23M | +42.4% |
| Q3 FY2019 | Sep 30, 2019 | $92.06M | +42.2% |
| Q2 FY2019 | Jun 30, 2019 | $86.71M | +41.0% |
| Q1 FY2019 | Mar 31, 2019 | $73.31M | +40.6% |
| Q4 FY2018 | Dec 31, 2018 | $69.67M | +29.8% |
| Q3 FY2018 | Sep 30, 2018 | $64.76M | +29.2% |
| Q2 FY2018 | Jun 30, 2018 | $61.51M | +60.3% |
| Q1 FY2018 | Mar 31, 2018 | $52.13M | +49.4% |
| Q4 FY2017 | Dec 31, 2017 | $53.66M | +77.4% |
| Q3 FY2017 | Sep 30, 2017 | $50.11M | – |
| Q2 FY2017 | Jun 30, 2017 | $38.38M | – |
| Q1 FY2017 | Mar 31, 2017 | $34.88M | – |
| Q4 FY2016 | Dec 31, 2016 | $30.24M | – |
See a number that looks wrong?